Bolt Biotherapeutics (BOLT) Net Margin (2020 - 2025)
Historic Net Margin for Bolt Biotherapeutics (BOLT) over the last 6 years, with Q3 2025 value amounting to 333.15%.
- Bolt Biotherapeutics' Net Margin rose 9969100.0% to 333.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 824.54%, marking a year-over-year decrease of 1111800.0%. This contributed to the annual value of 881.57% for FY2024, which is 29900.0% down from last year.
- Per Bolt Biotherapeutics' latest filing, its Net Margin stood at 333.15% for Q3 2025, which was up 9969100.0% from 477.33% recorded in Q2 2025.
- Over the past 5 years, Bolt Biotherapeutics' Net Margin peaked at 293.63% during Q1 2024, and registered a low of 5345.87% during Q4 2021.
- In the last 5 years, Bolt Biotherapeutics' Net Margin had a median value of 1145.17% in 2023 and averaged 1508.48%.
- As far as peak fluctuations go, Bolt Biotherapeutics' Net Margin skyrocketed by 39286400bps in 2022, and later plummeted by -6869800bps in 2024.
- Quarter analysis of 5 years shows Bolt Biotherapeutics' Net Margin stood at 5345.87% in 2021, then skyrocketed by 73bps to 1417.22% in 2022, then skyrocketed by 40bps to 857.01% in 2023, then tumbled by -55bps to 1330.06% in 2024, then surged by 75bps to 333.15% in 2025.
- Its last three reported values are 333.15% in Q3 2025, 477.33% for Q2 2025, and 905.24% during Q1 2025.